Ani Pharmaceuticals (ANIP) Change in Receivables (2012 - 2026)

Ani Pharmaceuticals (ANIP) has 15 years of Change in Receivables data on file, last reported at -$25.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 1332.55% year-over-year to -$25.5 million; the trailing twelve-month figure through Mar 2026 stood at $34.8 million (up 287.95% YoY), and the FY2025 full-year result was $58.5 million, up 177.56% from the prior year.
• Change in Receivables declined to -$25.5 million in Q1 2026, from $27.9 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $27.9 million in Q4 2025 to a low of -$25.5 million in Q1 2026.
• A 5-year average of $5.2 million and a median of $5.5 million in 2025 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables surged 2333.29% in 2022 and plunged 1332.55% in 2026, its largest moves.
• Tracing ANIP's Change in Receivables over 5 years: stood at $25.0 million in 2022, then slumped by 167.04% to -$16.8 million in 2023, then soared by 252.2% to $25.5 million in 2024, then increased by 9.18% to $27.9 million in 2025, then plunged by 191.64% to -$25.5 million in 2026.
• Business Quant data shows ANIP's Change in Receivables at -$25.5 million in Q1 2026, $27.9 million in Q4 2025, and $27.0 million in Q3 2025.